Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis.
bone cancer
image-guided
intensity-modulated
osteosarcoma
radiotherapy
sarcoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 02 2021
10 02 2021
Historique:
received:
29
12
2020
revised:
31
01
2021
accepted:
07
02
2021
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients' response to radiation. We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000-2010 and 2011-2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients' survival. A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000-2010 and that performed in the years 2011-2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%-43%)). RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.
Sections du résumé
BACKGROUND
Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients' response to radiation.
METHODS
We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000-2010 and 2011-2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients' survival.
RESULTS
A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000-2010 and that performed in the years 2011-2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%-43%)).
CONCLUSIONS
RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.
Identifiants
pubmed: 33578676
pii: cells10020366
doi: 10.3390/cells10020366
pmc: PMC7916348
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):820-8
pubmed: 15936566
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):492-8
pubmed: 15667972
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Mayo Clin Proc. 2003 Feb;78(2):147-55
pubmed: 12583525
Med Oncol. 2012 Dec;29(5):3431-9
pubmed: 22815154
Clin Orthop Relat Res. 2002 Apr;(397):40-52
pubmed: 11953594
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20511-20516
pubmed: 31548420
Langenbecks Arch Surg. 2003 Jan;387(9-10):355-65
pubmed: 12536331
Eur J Cancer. 2009 Sep;45(14):2447-51
pubmed: 19596190
Diagnostics (Basel). 2020 Dec 25;11(1):
pubmed: 33375764
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080914
Cancers (Basel). 2020 Dec 05;12(12):
pubmed: 33291477
J Cell Biochem. 2012 Apr;113(4):1282-91
pubmed: 22109788
Cancer Treat Res. 2009;152:147-64
pubmed: 20213389
Arch Orthop Trauma Surg. 2020 Jun 6;:
pubmed: 32506177
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Int J Mol Sci. 2020 Sep 30;21(19):
pubmed: 33007844
Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):687-91
pubmed: 3700173
Cancers (Basel). 2020 Mar 16;12(3):
pubmed: 32187978
Cancer. 2012 Sep 15;118(18):4555-63
pubmed: 22359113
Radiother Oncol. 2016 Apr;119(1):14-21
pubmed: 26718153
Front Oncol. 2020 Feb 04;10:82
pubmed: 32117737
J Natl Compr Canc Netw. 2017 Feb;15(2):155-167
pubmed: 28188186
Int J Radiat Biol Relat Stud Phys Chem Med. 1977 Mar;31(3):295-9
pubmed: 300732
Front Oncol. 2020 Jun 05;10:993
pubmed: 32582558
Int J Radiat Oncol Biol Phys. 1981 May;7(5):593-5
pubmed: 6944301
Sarcoma. 2014;2014:418270
pubmed: 25548538
Oncotarget. 2018 May 1;9(33):22976-22985
pubmed: 29796166
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301